PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates
News Feb 07, 2012
The new addition was unveiled at the 1st annual Society for Laboratory Automation and Screening Conference, in San Diego.
The expansion of the Epigenetic Biochemical Toolbox increases the portfolio to over 35 validated enzymatic assays for the detection of post-translational modifications of histone H3 and p53. The assays cover all the major writer and eraser enzyme families including HDACs, Sirtuins, HATs, HMTs and demethylases. This newly expanded portfolio helps researchers explore epigenetics-based therapeutic candidates for cancer and neurodegenerative disorders.
"This new addition to our epigenetics portfolio is part of a series of innovations to create a full breadth of offerings to advance personalized medicine research," said Kevin Hrusovsky, president, Life Sciences and Technology, PerkinElmer. "We are taking active steps to continue to transform PerkinElmer into one of the leading providers of technologies, services and products to enable researchers in this expanding market."
The new AlphaLISA(R) Epigenetic Cellular Detection Kits enable rapid and direct detection of endogenous modification of epigenetic marks on Histone H3, all in a one-well, no-wash assay format.
"The study of epigenetics is rapidly growing and presents opportunities for drug discovery, resulting in an increased need for high quality reagents," said Mark Roskey, vice president and general manager, Reagents, Life Sciences and Technology, PerkinElmer. "We now provide the most comprehensive reagent portfolio for epigenetic drug discovery. Our solutions are highly validated with detailed, ready-to-use protocols, and optimized for simplicity and throughput, marking our commitment to this expanding area of research."
PerkinElmer's epigenetic portfolio provides researchers access to fully validated reagents and assay development services that offer valuable time savings in the race to discover novel drug candidates. These highly specific reagents along with PerkinElmer's knowledge support for the development of epigenetic assays allow researchers to identify and characterize their lead compounds more quickly and efficiently.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018